1. Home
  2. Medicines: our clinical trials
  3. Clinical Studies
  4. CDT : Clinical Studies (current)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date Planned End date

A multicenter, open-label, phase 1 study investigating the safety and tolerability of encorafenib monotherapy in BRAFV600E-mutated Chinese patients with advanced metastatic solid tumors

 		Oncology Phase I Completed September 2021 May 2022

Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR

 		Oncology Real world study Completed July 2020 September 2024

The performance and safety of Petit Drill in the French paediatric population: a post-marketed clinical follow-up.

 		Otorhinolaryngology Real world study Early termination March 2024 November 2024

Advanced breast cancer patients treated with oral vinorelbine: a prospective and retrospective, observational study – VINOREAL

 		Oncology Real world study Recruiting May 2023 June 2028

An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world set

 		Oncology Real world study Recruiting January 01, 2025

A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)

 		Dermatology Phase II Recruiting April 2022 January 2029
21 - 26 over 26

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA